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Abstract
Importance—Federal legislation has led to a notable increase in pediatric studies submitted to
the Food and Drug Administration (FDA), resulting in new pediatric information in product
labeling. However, approximately 50% of drug labels still have insufficient information on safety,
efficacy, or dosing in children. Neonatal information in labeling is even scarcer because neonates
comprise a vulnerable subpopulation for which end point development is lagging and studies are
more challenging.
Objective—To quantify progress made in neonatal studies and neonatal information in product
labeling as result of recent legislation.
Design—1. Cohort of neonatal drug studies; and 2. Cohort of infants exposed to these drugs..
Setting—1. Neonatal drug studies: FDA website; 2. National review: infants admitted to a
neonatal intensive care unit (NICU)
Participants—1) We identified drug studies between 1997 and 2010 that included neonates as a
result of pediatric legislation using information available on the FDA website. We determined
what studies were published in the medical literature, the legislation responsible for the studies,
and the resulting neonatal labeling changes. 2) We then examined the use of these drugs in
neonates admitted to 290 NICUs (the Pediatrix Data Warehouse) in the United States from 2005–
2010.
Exposures—Infants exposed to a drug studied in neonates as identified by the FDA website
Main outcome measures—Number of drug studies with neonates and rate of exposure per
1000 admission among infants admitted to a NICU
Results—In a review of the FDA databases, we identified 28 drugs studied in neonates and 24
related labeling changes. Forty-one studies encompassed the 28 drugs, and 31 (76%) of these were
published. Eleven (46%) of the 24 neonatal labeling changes established safety and effectiveness.
In a review of a cohort of 446,335 hospitalized infants, we identified 399 drugs used and
1,525,739 drug exposures in the first 28 postnatal days. Thirteen (46%) of the 28 drugs studied in
neonates were not used in NICUs; 8 (29%) were used in fewer than 60 neonates. Of the drugs
studied, ranitidine was used most often (15,627 neonates, 35 exposures per 1000 admissions).
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Conclusions and Relevance—Few drug labeling changes made under pediatric legislation
include neonates. Most drugs studied are either not used or rarely used in U.S. NICUs.
Strategies to increase the study of safe and effective drugs for neonates are needed.
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Neonates, typically defined as infants up to 28 days of age, are at high risk of catastrophic
drug-related adverse events. Their unique physiology prevents successful extrapolation of
pharmacokinetic data from older patients, and appropriate dosing for most therapeutic
agents used in neonates is unknown.1 Despite neonatal medicine’s history of catastrophic
adverse events resulting from inadequate study of drugs prior to their widespread use,2–5 the
majority of drugs used in neonates have not undergone sufficient study to receive Food and
Drug Administration (FDA) labeling that is safe and effective when applied to this
population.6–10
Since 1997, a combination of pediatric incentives and requirements has significantly
increased pediatric drug research and development and stimulated an increase in pediatric
labeling.11–14 The legislation encompassing these initiatives was permanently reauthorized
in 2012.15 A large number of pediatric labeling changes have resulted from these policies16;
however, approximately 50% of drug product labeling has insufficient information on the
safety, efficacy, or dosing appropriate for use in children.17
We analyzed the effect of recent pediatric initiatives on neonatal studies and labeling. We
determined whether studies conducted under pediatric legislation included neonates, if there
was a labeling change that included neonates, and the types of neonatal labeling changes
made (e.g., if safety and effectiveness were established). We also identified the proportion of




We reviewed the pediatric resources on the FDA website for studies submitted between
1997 and 2010, including 1) the pediatric labeling changes database, 2) medical, statistical,
and clinical pharmacology reviews, 3) pediatric medical and clinical pharmacology
summaries, and 4) reviews posted at Drugs@FDA,16,18–20 to identify pediatric studies and
labeling changes that included neonates. We defined a neonate as any infant ≤28 postnatal
days of age. In cases where we could not identify the exact postnatal age, we included the
review and labeling change if it referred to an infant <1 postnatal month, “0” for the lower
limit of ages (e.g., 0 years of age), or “newborn.” We identified all drugs with pediatric
studies that included neonates, the indication studied, the number of pediatric studies for
each drug including neonates, the number of those studies published, the number of neonates
studied if specified, the legislation responsible for the study, and whether the drug was
approved for use in neonates for the indication studied. We compared the studies identified
in FDA reviews to the medical literature (MEDLINE) to determine the proportion of studies
identified in the reviews that were published.
NATIONAL REVIEW
We assembled a cohort of neonates (infants up to 28 days of age) from 2005–2010 using a
de-identified dataset that included infants discharged from 290 neonatal intensive care units
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(NICUs). The data were obtained from an administrative database that prospectively
captures information from daily progress notes generated by clinicians using a computer-
assisted tool on all infants cared for by the Pediatrix Medical Group. From the daily notes,
data were extracted, de-identified (in compliance with the Health Insurance Portability and
Accountability Act of 1996), and consolidated into the Pediatrix BabySteps Clinical Data
Warehouse. The “medications” and “demographics” tables were used for our analysis. We
included all neonates. We used standard summary statistics to describe drug use. We
searched the drug list for drugs that were identified in the FDA review to determine the
exposure among neonates. The Duke University Institutional Review Board designated this
study as exempt due to the de-identified nature of the data. The FDA’s institutional review
board exempted the national review from Research Involving Human Subject Committee
review.
RESULTS
We identified 28 drugs with 41 studies resulting in 24 labeling changes (including addition
of pharmacokinetic information) that included neonates (Table). Of the 28 drugs, 16 had
studies conducted under the incentive, 3 under the requirement, and 9 were conducted under
both. Between 1997 and 2010, as a result of the pediatric initiatives, a total of 406 pediatric
labeling changes were made.16 Twenty-four (6%) of the 406 pediatric labeling changes
included new neonatal information (Table, Figure; note that linezolid received 2 labeling
changes). Fourteen (50%) of the drugs were for infectious diseases, including 8 antiviral
drugs, 4 topical ophthalmic antibiotics, 1 antifungal, and 1 antibiotic. The remaining drugs
included 5 for gastroesophageal reflux disease (GERD), 3 anesthetics, 3 cardiovascular
drugs, 1 analgesic/antipyretic, 1 pulmonary drug, and 1 volume replacement. The majority
of the studies identified in the FDA review were published in the medical literature (31/41,
76%).
Eleven (46%) of 24 labeling changes including new neonatal information also included an
approval for use in neonates: 4 for HIV (didanosine, lopinavir/ritonavir, nevirapine, and
stavudine), 3 for anesthesia (remifentanil, rocuronium, and sevoflurane), and 4 for other
conditions (Table). Thirteen (54%) of the 24 neonatal labeling changes included the
statement “safety and effectiveness have not been established”: acetaminophen IV,
caspofungin, emtricitabine, esomeprazole magnesium, lamivudine, lansoprazole, linezolid,
nelfinavir, nitric oxide, pantoprazole, ranitidine, sotalol, and valganciclovir (Table).
Five of the products studied in neonates did not obtain a neonatal labeling change. Prior to
2007, it was possible to enroll children in studies and not have any information from the
study included in labeling. Moxifloxacin ophthalmic had a pediatric labeling change, but no
neonatal information was added; no pediatric labeling change was made for bivalirudin,
ciprofloxacin ophthalmic, gatifloxacin ophthalmic, or ofloxacin ophthalmic.
We found that 22/28 (79%) drugs clearly specified the number of neonatal participants in
the review, summary, or labeling; 6/28 (21%) provided only the number of pediatric
participants in a pediatric age range (e.g., 0–3 months) and ranged from 1 to over 200
neonates. The largest proportion of neonates was enrolled in 3 studies of inhaled nitric oxide
for the prevention of bronchopulmonary dysplasia (2180/3215, 68%); this drug failed to
prevent bronchopulmonary dysplasia.
PEDIATRIX DATABASE
We identified 399 drugs prescribed to 446,335 hospitalized neonates. Of the 28 drugs
studied, the gastroesophageal reflux drugs were used most often (Table): ranitidine was the
drug used most often (n=15,627 neonates; 35 exposures per 1000 neonates), lansoprazole
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was third (n=2374 neonates; 5.3 per 1000 neonates), and famotidine fourth (n=1646
neonates; 3.7 per 1000 neonates). Inhaled nitric oxide was the second most used drug
overall, with 4929 neonates exposed (11 per 1000 neonates).
Thirteen of the 28 drugs studied in neonates were not used in the Pediatrix neonatal
population (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, bivalirudin,
didanosine, emtricitabine, esomeprazole magnesium, fenoldopam, gatifloxacin ophthalmic
solution, lopinavir/ritonavir, nelfinavir, remifentanil, sevoflurane, stavudine, and
valganciclovir).
Eight of 28 were used in fewer than 60 neonates per drug (acetaminophen IV, ciprofloxacin
ophthalmic, lamivudine, nevirapine, ofloxacin ophthalmic, pantoprazole, rocuronium,
sotalol). Seven were used in more than 60 neonates per drug (caspofungin, famotidine,
lansoprazole, linezolid, moxifloxacin, nitric oxide, ranitidine). Of the 11 drugs with a
neonatal indication, 7 were never used in the Pediatrix neonatal population: 6%
hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, didanosine, fenoldopam,
lopinavir/ritonavir, remifentanil, sevoflurane, and stavudine. The other 4 drugs were used
infrequently: famotidine, 3.7 per 1000 neonates; linezolid, 0.9 per 1000 neonates; and
nevirapine and rocuronium, both <0.1 per 1000 neonates (Table).
The majority of labeling changes occurred prior to 2008 (18/28 drugs, 64%). Ten (36%) of
the drugs received labeling changes in the latter 3 years of the study period (2008–2010). Of
these, 2 of the 10 were in the top 3 drugs used in the NICU (lansoprazole: n=2374 and
inhaled nitric oxide: n=4929; both with no efficacy established).
DISCUSSION
Neonates are an understudied population. Several factors are considered before neonatal
studies can be performed: there must be a public health benefit, and the studies must be
feasible, ethical, and sufficient to support dosing, safety, and efficacy. Nearly 40% (11/28)
of the drugs involving neonates pursuant to pediatric legislation between 1997 and 2010
were deemed safe and effective in neonates. Most of these were drugs used to treat
infectious diseases (e.g., didanosine, lopinavir/ritonavir, and nevirapine), as well as
anesthesia drugs (e.g., remifentanil and rocuronium). Of the infectious disease drugs, the
majority were for HIV. Although neonatal HIV has been almost eradicated from the United
States, it is critical to study HIV drugs because it remains a problem in developing countries.
Thirteen drugs studied received a labeling change stating that “safety and effectiveness have
not been established” (Table). This is not surprising because neonates are a challenging
population to study. There is considerable variability in drug metabolism and physiology
within the neonatal population, which influences the pharmacokinetics, pharmacodynamics,
safety, and efficacy of medications. Neonates are typically enrolled in pharmacokinetic/
pharmacodynamic, safety, and dose-finding studies first; once an appropriate dose is
established, safety and efficacy studies may be done. The sample size for most neonatal
studies is very small due to the limitations inherent to these trials, including: low study
consent rates for parents of vulnerable infants; limited blood volume available to conduct
pharmacokinetic studies; lack of pediatric population pharmacokinetic/pharmacodynamic
analysis expertise; difficulties associated with timing of blood samples in critically ill
infants; lack of availability of sensitive drug concentration assays from very-small-volume
specimens (e.g., dried blood spots); and lack of robust clinical end points.49
We found that 13 drugs studied in neonates were not used at all among over 400,000
hospitalized neonates. One reason may be that there is a disparity between the drugs being
studied in neonates (particularly HIV drugs) and the conditions of patients in the Pediatrix
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database; 6 of the 13 drugs studied, but not used, were for HIV or HIV complications. Four
drugs failed to receive a neonatal indication, including 1 to treat HIV, so it is possible that
this is the reason that clinicians chose not to use these medications. The other products were
for rare conditions that are not represented in the assessed population or would be used
outside of the NICU: 2 were anesthetics not used in the NICU, 1 was for a rare
cardiovascular condition, and 1 was for volume replacement (Table). It is possible that,
because nearly one third of the labeling changes occurred in the last 3 years of the study
period, we did not capture their use because of a delay in uptake by clinicians. However,
only 3 of the 10 labeling changes during that time period had “safety and efficacy
established,” so we would not expect the drug to be used, and 2 of the 3 were HIV drugs, a
rare condition in the United States, making it unlikely that extending the national review
would identify increasing use of these drugs. Many factors influence drug selection in
neonates, including the current standard of care, availability of the drug in the hospital
formulary, and the level of comfort using a given drug in neonates in light of the existing
knowledge base.
Few hospitalized neonates were exposed to a drug approved for use in neonates as a result of
federal legislation (<0.5% of all drug exposures in neonates). We found that most of the
exposure to drugs was off-label for neonates; only a minority of neonates received a drug
approved for use in neonates (Table). Drugs that were used most often were used off-label
despite studies indicating they were not effective for the indication studied. For example,
ranitidine, lansoprazole, and inhaled nitric oxide (for the prevention of bronchopulmonary
dysplasia) were the top 3 drugs used in neonates (representing 91% of all drug exposures in
neonates from the 28 drugs studied); however, none have FDA labeling for the indication
studied because of lack of efficacy. Gastroesophageal reflux is difficult to diagnose and
treat, particularly in neonates. Unfortunately, anti-reflux medications, such ranitidine and
lansoprazole, are associated with serious side effects in neonates,50 and quality improvement
efforts in the Pediatrix Medical Group have reduced exposure in this vulnerable population.
Although inhaled nitric oxide use is approved in term and near-term infants for hypoxic
respiratory failure, it failed to prevent bronchopulmonary dysplasia and is not
recommended.51 Thus, many neonates are exposed to drugs that are not indicated in this
population, exposing them to unnecessary adverse events without the possibility of clinical
benefit.
There are several potential limitations to our study. Unfortunately, we could not identify the
number of neonatal participants who were in 6 studies of the drugs with publicly available
information from the FDA reviews and labeling. We could not determine the clinical
indication for use of drugs in the Pediatrix data. For drugs that are most often used for
surgery, such as remifentanil and rocuronium, we most likely underestimated the exposure
because we did not capture drugs that were used in the operating room. Finally, we only
include neonates who were hospitalized. For premature infants, this is most likely a
representative sample. However, our database does not include outpatient neonates, such as
neonates who were discharged well from the term nursery.
In conclusion, federal legislation encouraging the study of products used in the pediatric
population has resulted in very few labeling changes that include new neonatal information.
Studying drugs in neonates is critical; however, due to scientific and regulatory challenges,
trials involving neonates are scant. The rapid physiological changes in the developing
neonate affect study design and end points. Study designs and procedures that are
appropriate in adults and older children may not be appropriate in neonates. Extrapolation of
efficacy from adults or older pediatric populations—a tool that can sometimes be used to
decrease the “trial burden” for the pediatric population—is less easily adapted to the
neonate. The Pediatric Exclusivity program is voluntary. Therefore, sponsors are not
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obligated to perform the pediatric studies outlined in the FDA’s written request.
Furthermore, appropriate formulations for use in neonates may not exist. Due to these
challenges of performing clinical trials in infants, few labeling changes have included infant-
specific information. Novel trial designs need to be developed, and appropriate study end
points must be identified and validated. Education of parents and caregivers regarding the
need for studies of drugs being given to neonates will also increase trial success. The
scientific and clinical research community will need to work together with the FDA to
conduct essential neonatal studies.
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